DMD and Duchenne muscular dystrophy: After this initial study, a series of studies conducted in the mdx mouse model and DMD patients demonstrated the utility of circulating miRNA as biomarkers to monitor disease severity and response to treatments aiming to restore the missing dystrophin protein [32–34].